GlassScriptPhysician profile
Nicholas Bahl
NPI 1083149777
$16,110.92
in general payments reported to CMS, 2019-2025
30 companies · $3,176 in 2025
The $3,176 reported for 2025 was more than what 86% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $137 · 2021: $124 · 2022: $23.86 · 2023: $5,308 · 2024: $6,457 · 2025: $3,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,583 · Education: $4,000 · Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,583.37 |
| Education | $4,000.00 |
| Food and Beverage | $2,357.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,176.43 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Medical Device Business Services, INC. | $4,929.92 | 2024-2025 | Enseal, Harmonic, Matrixorthognathic |
| Tela Bio, INC. | $1,830.34 | 2024 | Ovitex 2s |
| Davol INC. | $1,067.73 | 2020-2025 | Phasix Mesh |
| Zimmer Biomet Holdings, INC. | $900.59 | 2024 | Advantagerib, Ribfix Blu Advantage |
| Allergan, INC. | $413.49 | 2019 | |
| Covidien LP | $225.78 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $212.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $178.16 | 2019-2023 | Farxiga |
| Depuy Synthes Sales INC. | $173.55 | 2024 | Matrixrib |
| Ethicon US, LLC | $156.33 | 2025 | Stratafix, Ethicon, N/A |
| Edwards Lifesciences Corporation | $126.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $122.70 | 2024-2025 | |
| Tactile Systems Technology INC | $96.16 | 2025 | Flexitouch Plus, Nimbl |
| Lilly USA, LLC | $81.34 | 2024-2025 | Zepbound, Taltz, Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $61.28 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Organogenesis INC. | $57.70 | 2023-2024 | Puraply |
| Blueprint Medicines Corporation | $33.28 | 2024 | Ayvakit |
| Abbvie INC. | $31.30 | 2024 | |
| Novartis Pharmaceuticals Corporation | $30.55 | 2025 | |
| Amgen INC. | $28.77 | 2024 | Repatha |
| Innovation Technologies INC | $26.23 | 2025 | Irrisept |
| Heron Therapeutics, INC. | $23.86 | 2022 | |
| Medtronic, INC. | $22.98 | 2024 | Minimed 780g |
| Merit Medical Systems INC | $21.98 | 2023 | Savi Scout |
| Xeris Pharmaceuticals, INC. | $17.58 | 2024 | Gvoke Hypopen |
| Ucb, INC. | $17.30 | 2025 | Bimzelx |
| Abbott Laboratories | $16.14 | 2024 | Eterna |
| Inari Medical, INC. | $15.48 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shire North American Group INC | $15.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Bahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.